pyridostigmine bromide · Us Army · NDA 020414, 217604
Pyridostigmine Bromide
Earliest generic entry, as listed · earliest of 2 marketed strengths
18 Jun 2038
1 of 2 marketed strengths has no unexpired patent or exclusivity listed; no marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10881617, US 10925833, US 10987311, US 11229606, US 11478425, US 11666536, US 11911515, US 12042559, US 12233166.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10881617 | product | 18 Jun 2038 |
| US 10925833 | product | 18 Jun 2038 |
| US 10987311 | product | 18 Jun 2038 |
| US 11229606 | product | 18 Jun 2038 |
| US 11478425 | product, use U-4012 | 18 Jun 2038 |
| US 11666536 | product | 18 Jun 2038 |
| US 11911515 | product | 18 Jun 2038 |
| US 12042559 | product | 18 Jun 2038 |
| US 12233166 | product | 18 Jun 2038 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020414 · 001 · discontinued | tablet, oral | 30MG | open |
| 217604 · 001 · discontinued | tablet, extended release, oral | 105MG | 18 Jun 2038 |